[{"orgOrder":0,"company":"Tolerance Bio","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"iPSC-based cell therapy","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Tolerance Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"Tolerance Bio \/ Columbus Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Tolerance Bio \/ Columbus Venture Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Tolerance Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The proceeds from the financing will be used to advance thymus-based therapies for immune-mediated diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 15, 2024

                          Lead Product(s) : iPSC-based cell therapy

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : Columbus Venture Partners

                          Deal Size : $17.2 million

                          Deal Type : Financing

                          blank